Investigation of the effect of Trimetazidine in patients with Aluminum phosphide poisoning

Evaluation of the effect of adding Trimetazidine to standard treatment of patients with Aluminum phosphide poisoning,referal to Loghman Hospital In Tehran? a pilot study on mortality

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211017052794N1

Enrollment

Registered

2022-04-13

Start date

2022-09-22

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Aluminum phosphide poisoning. Poisoning by unspecified drugs, medicaments and biological substances, accidental (unintentional)

Interventions

Intervention 1: Biogaran tablets with the chemical composition of Trimetazidine, 35 mg, which is used orally every 12 hours for 5 days. This drug is made by the French company Biogaran. During this 5-

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Consumption of oral form of Aluminium phosphide and referrs to Loghman Hospital under 24 hours and the presence of symptoms consistent with poisoning Positive silver nitrate test Carbon monoxide levels above 10 in non-smokers

Exclusion criteria

Exclusion criteria: Glomerular Filtration Rate(GFR) less than 30 (if available ),history of renal failure , history of liver failure , history of acute myocardial infarction, history of heart failure, history of congenital heart disease Pregnancy and lactation Refer to hospital after 24 hours

Design outcomes

Primary

Measure	Time frame
Mortality. Timepoint: During hospitalization. Method of measurement: Death during admission.	—

Secondary

Measure	Time frame
Admit duration. Timepoint: Period of time. Method of measurement: Daily chart.;Icu admission. Timepoint: Number of hospitalization days. Method of measurement: Daily chart.;Arrhythmia. Timepoint: Daily electrocardiogram/As long as the patient is being treated with trimetazidine. Method of measurement: Electrocardiogram.;Need for inotropic drugs. Timepoint: Number of hospitalization days. Method of measurement: Based on blood pressure less than 90 mmHg and inotrop drugs initiation recorded in the chart.;Left ventricle ejection fraction. Timepoint: Second day of admission. Method of measurement: Echocardiography.;Intubation. Timepoint: Hospital admission. Method of measurement: Number of intubation patients registered in the chart.	—

Measure

Time frame

Admit duration. Timepoint: Period of time. Method of measurement: Daily chart.;Icu admission. Timepoint: Number of hospitalization days. Method of measurement: Daily chart.;Arrhythmia. Timepoint: Daily electrocardiogram/As long as the patient is being treated with trimetazidine. Method of measurement: Electrocardiogram.;Need for inotropic drugs. Timepoint: Number of hospitalization days. Method of measurement: Based on blood pressure less than 90 mmHg and inotrop drugs initiation recorded in the chart.;Left ventricle ejection fraction. Timepoint: Second day of admission. Method of measurement: Echocardiography.;Intubation. Timepoint: Hospital admission. Method of measurement: Number of intubation patients registered in the chart.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Sheibani

Shahid Beheshti University of Medical Sciences

mesheibani@yahoo.com+98 21 5102 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026